Rationale for Treatment of mNSCLC with Immune Checkpoint Inhibitors

Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.

Related Videos
Expert on NSCLC
Expert on NSCLC
Expert on NSCLC
Experts on NSCLC
Expert on NSCLC
Expert on NSCLC
Related Content